Reported 0 shares, down 19,764 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 141000 |
| 2022-03-31 | 160000 |
| 2022-06-30 | 88000 |
| 2022-09-30 | 142000 |
| 2022-12-31 | 131154 |
| 2023-03-31 | 81294 |
| 2023-06-30 | 261214 |
| 2023-09-30 | 231343 |
| 2023-12-31 | 258492 |
| 2024-03-31 | 852224 |
| 2024-06-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2024 | Reduced | 0 | -19,764 (-100.0%) | 0 | $0 | 2024-08-13 | |
| Q1 2024 | Added | 19,764 | +2,957 (17.6%) | < 0.01% | $852,224 | 2024-05-13 | |
| Q4 2023 | Reduced | 16,807 | -67 (-0.4%) | < 0.01% | $258,492 | 2024-02-13 | |
| Q3 2023 | Added | 16,874 | +599 (3.7%) | < 0.01% | $231,343 | 2023-11-13 | |
| Q2 2023 | Added | 16,275 | +5,799 (55.4%) | < 0.01% | $261,214 | 2023-08-04 | |
| Q1 2023 | Added | 10,476 | +3,698 (54.6%) | < 0.01% | $81,294 | 2023-05-12 | |
| Q4 2022 | Added | 6,778 | +127 (1.9%) | < 0.01% | $131,154 | 2023-02-10 | |
| Q3 2022 | Added | 6,651 | +163 (2.5%) | < 0.01% | $142,000 | 2022-11-14 | |
| Q2 2022 | Reduced | 6,488 | -306 (-4.5%) | < 0.01% | $88,000 | 2022-08-12 | |
| Q1 2022 | Added | 6,794 | +1,535 (29.2%) | < 0.01% | $160,000 | 2022-05-13 | |
| Q4 2021 | Added | 5,259 | +1,392 (36.0%) | < 0.01% | $141,000 | 2022-02-11 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
195 managers reported VERA THERAPEUTICS INC for Q2 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | Reduced | 4,309,590 | -955,410 | 2.08% | $155,920,966 | 2 qtrs |
| PRICE T ROWE ASSOCIATES INC MD | Added | 3,620,135 | +1,227,106 | 0.02% | $130,977,000 | 2 qtrs |
| BlackRock Inc | Added | 3,337,672 | +18,708 | < 0.01% | $120,756,973 | 13 qtrs |
| FMR LLC | Reduced | 2,801,938 | -321,330 | < 0.01% | $101,374,117 | 13 qtrs |
| Sofinnova Investments Inc | Unchanged | 2,793,987 | 0 | 5.25% | $101,086,450 | 13 qtrs |
| VANGUARD GROUP INC | Added | 2,524,176 | +375,462 | < 0.01% | $91,324,688 | 13 qtrs |
| COMMODORE CAPITAL LP | Reduced | 2,475,000 | -690,000 | 6.11% | $89,545,500 | 6 qtrs |
| STATE STREET CORPORATION | Reduced | 2,155,553 | -195,174 | < 0.01% | $77,987,908 | 12 qtrs |
| Eversept Partners LP | Added | 2,043,214 | +219,433 | 5.06% | $73,923,483 | 8 qtrs |
| Holocene Advisors LP | Added | 1,796,077 | +588,697 | 0.27% | $64,982,066 | 2 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2024
- Filed
- August 13, 2024
- Filing type
- 13F-HR
- Position type
- CL A
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.